Skip to main content
. Author manuscript; available in PMC: 2020 Sep 2.
Published in final edited form as: Invest New Drugs. 2017 Mar 10;35(5):627–633. doi: 10.1007/s10637-017-0444-1

Table 4.

Summary of Disease Response


Number (%) of Patients

Characteristic Part 1 (N=12) Part 2 (N=29) Total (N=41)
Best Overall Response
  Complete Response (CR) 0 0 0
  Partial Response (PR) 1 (8.3) 0 1 (2.4)
  Stable Disease (SD) 5 (41.7) 16 (55.2) 21 (51.2)
  Progressive Disease (PD) 3 (25.0) 6 (20.7) 9 (22.0)
  Not Evaluable 3 (25.0) 7 (24.1) 10 (24.4)
Overall Response Rate (CR+PR) 1 (8.3) 0 1 (2.4)